In accordance with the Rules and Procedures of the Council of Experts, the Small Molecules 4 Expert Committee has revised the Carbamazepine Extended-Release Tablets monograph. The purpose of this revision is to add *Dissolution Test 7* to accommodate FDA-approved drug products with different dissolution conditions and/or tolerances than the existing dissolution test(s).

- *Dissolution Test 7* was validated using the X-Bridge C18 brand of column with L1 packing. The typical retention time for carbamazepine is about 4 min.

The Carbamazepine Extended-Release Tablets Revision Bulletin supersedes the currently official monograph.

Should you have any questions, please contact Yanyin Yang, Senior Scientist II (301-692-3623 or yanyin.yang@usp.org).